PUFA Augmentation in Treatment of Major Depression
Status:
Completed
Trial end date:
2007-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if omega-3 fatty acid EPA will enhance and speed up
response to antidepressant therapy with Celexa (Citalopram) in people suffering from Major
Depressive Disorder. All patients will receive Celexa, 50% will receive EPA, 50% placebo EPA.
Phase:
Phase 3
Details
Lead Sponsor:
National Center for Complementary and Integrative Health (NCCIH)